Latest news for Hemostemix (OTC:HMTXF) Stock

Hemostemix Inc is a biotechnology company. The company's principal business activity is developing, manufacturing, and commercializing blood-derived cell therapies for medical conditions. The Company's technology is a platform for developing autologous cell therapies to treat vascular diseases. The Company's clinical stage consists of ACP-01, autologous cell therapy for the treatment of critical limb ischemia.

Biotech

Cannabis

News

Penny Stocks

Emerging Markets

Markets

General

ACOGF

BABYF

EMMA

HMTXF

JNHMF

MCURF

RDHL

RLFTF

RSLS

RSPI

SLRX

VNRX

TSXV:ACOG

TSXV:HEM

TSXV:BABY

Photo by Chris Montgomery on Unsplash

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

Epigenetics, Psychedelics and Stem Cell Therapy are Topics of the Life Sciences Virtual Investor Conference Launching This Thursday

Hemostemix Inc

Kevin Richardson, Chief Executive Officer, Telix Precision Medicine commented,&nbsp;"We are delighted by this positive outcome, setting the stage for a European commercial launch of Illuccix."

Telix Receives Positive Decision On Marketing Authorization Application For Its Prostate Cancer PET Imaging Agent Illuccix, Which Was Submitted In Europe

PRTS

CarParts.com Regains Compliance With Nasdaq's Minimum Bid Price Requirement Listing Rule

AEVA

Aeva To Transfer Stock Exchange Listing Of Its Common Stock And Warrants To Nasdaq Global Select Market From NYSE; Ticker Symbol To Remain 'AEVA'

Nukkleus Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>) shares are trading higher in Thursday&#8217;s after-hours session after the strategic acquisition company announced it <a href="https://www.benzinga.com/pressreleases/25/01/n43040329/nukkleus-inc-successfully-resolves-nasdaq-delisting-threat-achieving-compliance-across-all-key-par">regained compliance with Nasdaq listing rules</a>.
What Happened: After the market close on Thursday, Nukkleus said it received notice on Wednesday that it successfully regained compliance with Nasdaq listing rules which require companies to maintain a minimum market value of listed securities and a minimum market value of publicly held shares.
Nukkleus effected a 1-for-8 reverse stock split on Oct. 24 to regain compliance with the $1 minimum bid price requirement for continued listing on the Nasdaq. Every eight shares of the company&#8217;s common stock were combined and reclassified into one share of common stock, reducing the number of issued and outstanding shares from 16.9 million to approximately 2.1 million.
Nukkleus on Thursday announced that the Nasdaq canceled the hearing scheduled for Jan. 21, confirming that the company&#8217;s shares will continue to trade on the Nasdaq.
&#8220;The management of the company believes this milestone underscores its effective resolution of all compliance matters with Nasdaq, allowing the company to continue its pursuit of sustainable growth and deliver lasting value to its stakeholders,&#8221; the Nukkleus said.
See Also: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/01/43041374/exclusive-how-high-will-sp-500-go-under-donald-trump-in-2025-readers-are-optimistic-26-say-this">EXCLUSIVE: How High Will S&amp;P 500 Go Under Donald Trump In 2025? Readers Are Optimistic, 26% Say This…</a>
<h1 class="wp-block-heading">How To Buy NUKK Stock</h1>
By now you're likely curious about how to participate in the market for Nukkleus — be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share. 
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading — either way it allows you to profit off of the share price decline.
NUKK Price Action: <a href="http://benzinga.com/quote/nukk">Nukkleus shares</a> were up 28.59% in after-hours, trading at $26.40 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

After-Hours Center

Movers

NUKK

Nukkleus Shares Are Soaring After Hours: Here's Why

10 analysts have shared their evaluations of Corpay (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPAY#NYSE">CPAY</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Corpay, revealing an average target of $389.5, a high estimate of $440.00, and a low estimate of $320.00. This current average has increased by 7.6% from the previous average price target of $362.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1737064864_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Corpay. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$375.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$415.00</td>
<td>$425.00</td>
</tr>
<tr>
<td>Rufus Hone</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$440.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$425.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Peter Christiansen</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$430.00</td>
<td>$405.00</td>
</tr>
<tr>
<td>James Faucette</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$350.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>James Faucette</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$325.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$415.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$320.00</td>
<td>$285.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Corpay. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Corpay compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Corpay's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Corpay's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CPAY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Corpay analyst ratings.</a>
<h2>About Corpay</h2>
Corpay Inc is a global S&amp;P500 corporate payments company that helps businesses and consumers pay expenses in a simple, controlled manner. Its suite of modern payment solutions helps its customers better manage vehicle-related expenses (such as fueling and parking), travel expenses (e.g. hotel bookings), and payables (e.g. paying vendors). This results in its customers saving time and ultimately spending less.
<h3>A Deep Dive into Corpay's Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Corpay's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.01% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 26.86%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Corpay's ROE excels beyond industry benchmarks, reaching 9.47%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Corpay's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.63%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Corpay's debt-to-equity ratio stands notably higher than the industry average, reaching 2.51. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

CPAY

Corpay Stock: A Deep Dive Into Analyst Perspectives (10 Ratings)

Analysts' ratings for Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) over the last quarter vary from bullish to bearish, as provided by 19 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">8</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Deckers Outdoor and provided 12-month price targets. The average target is $208.05, accompanied by a high estimate of $246.00 and a low estimate of $170.00. This upward trend is evident, with the current average reflecting a 9.38% increase from the previous average price target of $190.21.
<img src="https://www.benzinga.com/files/images/story/2025/1737064847_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Deckers Outdoor's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Civello</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$235.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$215.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>JESALYN Wong</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$235.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Tom Nikic</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$246.00</td>
<td>$226.00</td>
</tr>
<tr>
<td>Jonathan Komp</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$225.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Ashley Owens</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$213.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Tom Nikic</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$226.00</td>
<td>$218.00</td>
</tr>
<tr>
<td>Joseph Civello</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$230.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Tom Nikic</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$218.00</td>
<td>-</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$232.00</td>
<td>$226.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>John Kernan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$185.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>JESALYN Wong</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$195.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Ashley Owens</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$181.00</td>
<td>$147.83</td>
</tr>
<tr>
<td>Christopher Nardone</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$182.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$170.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Jonathan Komp</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$195.00</td>
<td>$180.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Deckers Outdoor. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Deckers Outdoor compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Deckers Outdoor's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Deckers Outdoor's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DECK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Deckers Outdoor analyst ratings.</a>
<h2>Delving into Deckers Outdoor's Background</h2>
Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2024, Ugg and Hoka accounted for 52% and 42% of total sales, respectively. The firm also markets niche brands Teva, Ahnu, and Koolaburra. Deckers generates most of its sales through wholesale partnerships, but also operates e-commerce in more than 50 countries and about 178 company-operated stores. The company generated 67% of its fiscal 2024 sales in the United States.
<h3>A Deep Dive into Deckers Outdoor's Financials</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Over the 3 months period, Deckers Outdoor showcased positive performance, achieving a revenue growth rate of 20.09% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Deckers Outdoor's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 18.48%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Deckers Outdoor's ROE excels beyond industry benchmarks, reaching 11.28%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Deckers Outdoor's ROA excels beyond industry benchmarks, reaching 7.23%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.12.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DECK

Forecasting The Future: 19 Analyst Projections For Deckers Outdoor

Ratings for Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Plug Power, revealing an average target of $4.46, a high estimate of $18.00, and a low estimate of $1.40. This current average has decreased by 28.75% from the previous average price target of $6.26. 
<img src="https://www.benzinga.com/files/images/story/2025/1737064836_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Plug Power among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$2.50</td>
<td>$2.00</td>
</tr>
<tr>
<td>Amit Dayal</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$5.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$2.00</td>
<td>$2.25</td>
</tr>
<tr>
<td>Eric Stine</td>
<td>Craig-Hallum</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$2.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$1.40</td>
<td>$1.60</td>
</tr>
<tr>
<td>James West</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$4.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$2.25</td>
<td>$2.50</td>
</tr>
<tr>
<td>Amit Dayal</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Plug Power. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Plug Power compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Plug Power's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Plug Power's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PLUG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Plug Power analyst ratings.</a>
<h2>Get to Know Plug Power Better</h2>
Plug Power is building an end-to-end green hydrogen ecosystem-from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.
<h3>Financial Insights: Plug Power</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Plug Power's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -12.57%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Plug Power's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -121.55%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Plug Power's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -7.02%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Plug Power's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -4.44%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Plug Power's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.31.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PLUG

A Glimpse Into The Expert Outlook On Plug Power Through 9 Analysts

Ratings for Dave &amp; Buster's Enter (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLAY#NASDAQ">PLAY</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $43.67, with a high estimate of $56.00 and a low estimate of $27.00. Observing a downward trend, the current average is 17.09% lower than the prior average price target of $52.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1737064828_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Dave &amp; Buster's Enter among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jake Bartlett</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$27.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Alton Stump</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Andrew Strelzik</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$47.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Jake Bartlett</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$36.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Andrew Strelzik</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$51.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Jake Bartlett</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$56.00</td>
<td>$59.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Dave &amp; Buster's Enter. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dave &amp; Buster's Enter compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Dave &amp; Buster's Enter's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Dave &amp; Buster's Enter's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PLAY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Dave &amp; Buster's Enter analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Dave &amp; Buster's Enter</h2>
Dave &amp; Buster's Entertainment Inc owns and operates nearly a hundred entertainment and dining establishments in the United States where customers can eat, drink, play games, and watch televised sports. Each store offers a full menu of entries and appetizers, a complete selection of alcoholic and non-alcoholic beverages, and an extensive assortment of entertainment attractions centered around playing games and watching live sports and other televised events. It derives maximum revenue from Entertainment.
<h3>Unraveling the Financial Story of Dave &amp; Buster's Enter</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Challenges: Dave &amp; Buster's Enter's revenue growth over 3 months faced difficulties. As of 31 October, 2024, the company experienced a decline of approximately -2.98%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: Dave &amp; Buster's Enter's net margin excels beyond industry benchmarks, reaching -7.22%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Dave &amp; Buster's Enter's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -12.8%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Dave &amp; Buster's Enter's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.84% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Dave &amp; Buster's Enter's debt-to-equity ratio stands notably higher than the industry average, reaching 13.76. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PLAY

A Glimpse Into The Expert Outlook On Dave & Buster's Enter Through 6 Analysts

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for DuPont de Nemours, revealing an average target of $98.29, a high estimate of $107.00, and a low estimate of $85.00. Holding firm without variation, the current average remains at the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2025/1737064819_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of DuPont de Nemours among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$101.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$92.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$104.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$107.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Duffy Fischer</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$85.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$94.00</td>
<td>$88.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to DuPont de Nemours. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DuPont de Nemours compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for DuPont de Nemours's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into DuPont de Nemours's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on DuPont de Nemours analyst ratings.</a>
<h2>Delving into DuPont de Nemours's Background</h2>
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics, water, construction, safety and protection, automotive, and healthcare industries. DuPont plans to separate the company into three companies going forward, one focused on electronics, one focused on water, and one with more diversified end market exposure. We expect the separations will occur by mid-2026.
<h3>DuPont de Nemours's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: DuPont de Nemours's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 4.38%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Materials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 14.22%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.91%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): DuPont de Nemours's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.23% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.29.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For DuPont de Nemours's Future

Analysts' ratings for AMETEK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AME#NYSE">AME</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $211.5, a high estimate of $225.00, and a low estimate of $186.00. This upward trend is evident, with the current average reflecting a 6.11% increase from the previous average price target of $199.33.
<img src="https://www.benzinga.com/files/images/story/2025/1737064810_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive AMETEK is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$222.00</td>
<td>$221.00</td>
</tr>
<tr>
<td>Andrew Obin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$225.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Steve Barger</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Richard Eastman</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$186.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Brett Linzey</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$221.00</td>
<td>$219.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to AMETEK. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of AMETEK compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of AMETEK's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of AMETEK's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AME/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AMETEK analyst ratings.</a>
<h2>Delving into AMETEK's Background</h2>
Founded in 1930 and transformed over the decades through the acquisition of dozens of esteemed brands, Ametek owns a collection of over 40 autonomous industrial businesses operating within the research, aerospace, energy, medical, and manufacturing industries. Ametek segments its business into two operating groups: the electronic instruments group (EIG) and electromechanical group (EMG). EIG sells a broad portfolio of analytical, test, and measurement instruments, while EMG sells highly engineered components, interconnects, and specialty metals. The company emphasizes product differentiation and market leadership in the niche markets where it operates.
<h3>AMETEK's Financial Performance</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, AMETEK showcased positive performance, achieving a revenue growth rate of 5.28% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: AMETEK's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 19.91%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): AMETEK's ROE stands out, surpassing industry averages. With an impressive ROE of 3.62%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): AMETEK's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.3% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: AMETEK's debt-to-equity ratio is below the industry average. With a ratio of 0.24, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 6 Analyst Ratings Have To Say About AMETEK

JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) has outperformed the market over the past 20 years by 1.69% on an annualized basis producing an average annual return of 10.14%. Currently, JPMorgan Chase has a market capitalization of $711.01 billion. 
Buying $1000 In JPM: If an investor had bought $1000 of JPM stock 20 years ago, it would be worth $6,894.52 today based on a price of $254.15 for JPM at the time of writing.
<h3>JPMorgan Chase's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737064809_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning JPMorgan Chase Stock In The Last 20 Years

Rasmussen is a seasoned financial executive with more than 25 years of experience, most recently serving as the CFO of National Vision.
As previously announced, Steve Heinrichs will transition from his Chief Financial Officer and Chief Legal and Compliance Officer roles and remain available to the Company on a consulting basis until September 30, 2025, to help ensure a smooth transition.

Management

Mueller Water Products Names Melissa Rasmussen As Its Senior Vice President And CFO, Effective March 4, 2025

The loan guarantee will help finance the construction of up to six projects to produce and liquify zero- or low-carbon hydrogen at scale throughout the United States. Plug's Graham, Texas, green hydrogen plant, the first to benefit from this financing, will create hundreds of high-quality jobs.

Plug Power Closes $1.66B Loan Guarantee From US Department Of Energy; Loan Guarantee Supports Company's Domestic Hydrogen Production Plant Buildout

Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) has outperformed the market over the past 5 years by 8.5% on an annualized basis producing an average annual return of 20.8%. Currently, Williams Companies has a market capitalization of $72.14 billion. 
Buying $100 In WMB: If an investor had bought $100 of WMB stock 5 years ago, it would be worth $257.19 today based on a price of $59.18 for WMB at the time of writing.
<h3>Williams Companies's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737063908_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Williams Companies 5 Years Ago Would Be Worth This Much Today

Company continues to expand global presence in battery materials space
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.icl-group.com%2F&amp;esheet=54181805&amp;newsitemid=20250116261144&amp;lan=en-US&amp;anchor=ICL&amp;index=1&amp;md5=20d38fb8e438f5aeb23fc33cf78eabdb">ICL</a> (NYSE:<a href="https://www.benzinga.com/stock/ICL#NYSE">ICL</a>) (TASE: ICL), a leading global specialty minerals company, today announced it has signed a joint venture (JV) agreement with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fdynanonic.com%2Fenindex.aspx&amp;esheet=54181805&amp;newsitemid=20250116261144&amp;lan=en-US&amp;anchor=Shenzhen+Dynanonic+Co.%2C+Ltd.&amp;index=2&amp;md5=245fb7628f2460dace062849ee85d2e2">Shenzhen Dynanonic Co., Ltd.</a> to establish lithium iron phosphate (LFP) cathode active material (CAM) production in Europe, with an initial investment of approximately &euro;285 million. A new facility at ICL&#39;s Sallent, Spain, site is currently in planning stages and will substantially expand the company&#39;s battery materials business. The project demonstrates ICL&#39;s commitment to developing high-quality solutions for a sustainable supply chain and represents a significant step forward for the company&#39;s battery materials portfolio, this time into Europe.

Contracts

ICL Expands Joint Venture With Shenzhen Dynanonic With Additional Investment Of €285 Million For European LFP Cathode Material Production

Safe Harbor Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHFS#NASDAQ">SHFS</a>), which provides secure and compliant financial services for the regulated <a href="https://www.benzinga.com/cannabis">cannabis industry</a>, announced it had surpassed $25 billion in processed cannabis-related funds through its network of partner banks.
This milestone aligns with the company&#8217;s 10th anniversary in a complex industry where many have succumbed to regulatory scrutiny.
"Our founding mission was to enhance community safety by providing a stable and compliant environment for legal cannabis companies. Reaching this threshold during our 10th anniversary is a landmark achievement that speaks to our unwavering commitment to supporting the cannabis industry with transparent, secure and scalable financial solutions,&#8221; Sundie Seefried, CEO of Safe Harbor Financial said in an email shared with Benzinga.
Since its founding in 2015, Safe Harbor has led the charge in addressing the burdensome financial challenges faced by the cannabis industry, such as <a href="https://www.benzinga.com/markets/cannabis/22/01/25268132/financial-regulator-calls-lack-of-banking-access-in-cannabis-a-serious-market-failure">not having access</a> to traditional banking and financial services due to cannabis' classification as a <a href="https://www.benzinga.com/markets/cannabis/24/02/36916329/is-marijuana-a-controlled-substance-wait-what-is-a-controlled-substance">Schedule I drug</a> and therefore illegal at the federal level.
Read More: <a href="https://www.benzinga.com/25/01/42972524/dea-judge-cancels-marijuana-rescheduling-hearing-amid-disturbing-allegations-of-improper-conduct">DEA Judge Cancels Marijuana Rescheduling Hearing Amid &#8216;Disturbing&#8217; Allegations Of Improper Conduct</a>
Safe Harbor, one of the first financial institutions to design solutions specifically for cannabis businesses, now serves clients across nearly 40 states and U.S. territories. The firm provides a full suite of financial products that enable businesses to operate with confidence in a heavily regulated environment.
"Over the past decade, we've built an unparalleled platform that empowers cannabis businesses to thrive while setting new standards for compliance, accountability and innovation in the financial sector," continued Seefried. "I couldn't be more proud of what we've accomplished and am excited about the opportunities ahead as we continue to drive the industry forward."
Eivan Shahara, co-founder and CEO of <a href="https://themintcannabis.com/" target="_blank" rel="noreferrer noopener">Mint Cannabis</a>, a vertical multi-state operator headquartered in Arizona, said Safe Harbor has been an essential partner in his company's journey.
"Their innovative approach to cannabis banking has enabled us to access critical financial services while maintaining full compliance with stringent state and federal regulations. As the industry grows and pushes for federal reform, Safe Harbor's expertise and leadership are more important than ever. We're proud to be part of their journey and look forward to achieving even greater success together."
Now Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/01/43040086/nra-warns-of-legal-confusion-over-guns-and-cannabis">NRA Warns Of Legal Confusion Over Guns And Cannabis: Could Fed Ban Expand?</a></li>
</ul>
Image created by AI

Financing

Small Cap

SHFS

$25 Billion And Counting: Safe Harbor Financial's Decade Of Keeping Cannabis Industry In The Green As Banks Remain Banned From Touching Marijuana Money

RIVN

CORRECTION: Rivian Secures $6.6B DOE Loan For New Georgia Facility, Creating 7.5K Jobs To Boost EV Production

Legal

GEO Group Comments On Ninth Circuit Court Ruling In Nwauzor Case, Maintains VWP Participants Are Not Employees; Plans To Appeal Ruling

American Express Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) has agreed to a $108.7 million settlement to resolve allegations of violating the Financial Institutions Reform, Recovery and Enforcement Act. The Department of Justice accused <a href="https://www.benzinga.com/quote/AXP/news">the financial giant</a> of deceptive marketing and falsified record-keeping between 2014 and 2021.
What To Know: From 2014 to 2017, American Express <a href="https://www.justice.gov/opa/pr/american-express-agrees-pay-1087m-settle-allegations-deceptive-marketing-and-dummy-account">allegedly </a>misled small business customers regarding credit card rewards, fees and credit checks, and submitted false income information.
Additionally, employees bypassed legal requirements by entering fabricated Employer Identification Numbers (EINs) on small business credit card applications during a product transition period, exacerbating compliance failures.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43031980/big-banks-continue-to-beat-q4-earnings-financial-etf-takes-breather">Big Banks Continue To Beat Q4 Earnings As Financial ETF Takes A Breather</a>
From 2018 to 2021, American Express was further accused of misrepresenting tax benefits for its Payroll Rewards and Premium Wire programs, charging above-market fees under false pretenses. 
Alongside the settlement, American Express entered a Non-Prosecution Agreement with the U.S. Attorney's Office, agreeing to a $30.35 million credit toward criminal fines and forfeitures.
Price Action: AXP shares closed marginally lower on Thursday, down 0.27% to $311.48.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, AXP has a 52-week high of $314.00 and a 52-week low of $177.81.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/25/01/42956034/netflix-stock-has-long-term-runway-for-dominance-in-streaming-analyst-highlights-4-key-catalysts" target="_blank" rel="noreferrer noopener">Netflix Stock Has ‘Long Term Runway For Dominance In Streaming': Analyst Highlights 4 Key Catalysts</a></li>
</ul>
Photo: Shutterstock

Government

American Express Settles $108.7 Million Compliance Case With Justice Department

Rivian Has Closed Its Loan Agreement With The U.S. Department Of Energy's Loan Programs Office For Up To $6.6B And ~$600M of Capitalized Interest

Hemostemix announces incorporation of Hemostemix PR

Press Releases

Hemostemix Announces Strategic Manufacturing Partnership with CytoImmune Therapeutics and $1,800,000 in Financing Commitments

Financing & Partnership News Send Shares of this Stem-Cell Therapy Company on a Tear

TSX:HEM

Hemostemix

Photo by Chris Montgomery on <a href="https://unsplash.com/photos/smgTvepind4">Unsplash</a>

The following post was written and/or published as a collaboration between Benzinga&rsquo;s in-house sponsored content team and a financial partner of Benzinga.

This year&rsquo;s <a href="https://www.virtualinvestorconferences.com/events/event-details/life-sciences-investor-forum-3?utm_source=121621LSIF&amp;utm_medium=article+&amp;utm_campaign=121621LSIF&amp;utm_id=120221SmallCapVIC">Life Sciences Investor Forum</a>, running from 9:30 a.m. to 3:30 p.m. Dec. 16, introduces 12 publicly listed life science companies aiming to improve the quality of human life.

From biopharmaceuticals and epigenetics to psychedelics and metabolic health, each company has chosen a niche through which to achieve this goal. Attendees, investors and stakeholders will watch and listen as each of these companies explains their latest ideas, prompting watchers to wonder: What new scientific development will change human life as we know it?

For ReShape Lifesciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>), the answer to this question may reportedly lie in its Food and Drug Administration (FDA)-approved Lap-Band&reg; Program, which provides a minimally invasive, long-term treatment for obesity. Meanwhile, VolitionRx Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#NYSE">VNRX</a>) will argue that its Nucleosomics&trade; platform will radically improve patients&rsquo; ability to catch and monitor life-changing diseases early. Mind Cure Health Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/MCURF#OTCQX">MCURF</a>) will posit that its research on the effect of digital therapeutics and psychedelic compounds on mental health will challenge our understanding of conventional mental health therapy. Nine more companies will post their arguments, but investors will only get to hear the full story at the forum.

The <a href="https://www.virtualinvestorconferences.com/events/event-details/life-sciences-investor-forum-3?utm_source=121621LSIF&amp;utm_medium=article+&amp;utm_campaign=121621LSIF&amp;utm_id=120221SmallCapVIC">Life Science Investor Forum</a> may present a window of opportunity for investors and traders, allowing them to hear exclusively from companies attempting to be health leaders of the future. The 1-day marathon event is free for everyone and requires only a simple email sign-up to join.&nbsp;

<h2>Life Sciences Investor Forum Agenda</h2>

A complete list of the agenda is available on the <a href="https://www.virtualinvestorconferences.com/events/event-details/life-sciences-investor-forum-3?utm_source=121621LSIF&amp;utm_medium=article+&amp;utm_campaign=121621LSIF&amp;utm_id=120221SmallCapVIC">Life Science Investor Forum</a>&rsquo;s main page.

Time: 9:30 a.m. EST&nbsp;

Company: <a href="https://www.redhillbio.com/investors/overview/default.aspx">RedHill BioPharma Ltd.</a>&nbsp;

Ticker: (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>)&nbsp;

Industry: Biopharmaceuticals &mdash; gastrointestinal and infectious diseases

Speaker information: Guy Goldberg, Chief Business Officer

Time: 10 a.m. EST&nbsp;

Company: <a href="https://www.otcmarkets.com/stock/RSPI/overview">RespireRx Pharmaceuticals Inc.</a>&nbsp;

Ticker: (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/RSPI#OTCQB">RSPI</a>)&nbsp;

Industry: Biopharmaceuticals &mdash; psychiatric and neurological disorders

Speaker information: Jeff Margolis, SVP, Treasurer, CFO and Member of Board of Directors

Time: 10:30 a.m. EST&nbsp;

Company:<a href="https://www.otcmarkets.com/stock/RLFTF/overview"> Relief Therapeutics Holding </a>SA

Ticker: (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/RLFTF#OTCQB">RLFTF</a>)

Industry: Biopharmaceuticals &mdash; respiratory and rare and specialty

Speaker information: Jack Weinstein, chief financial officer and treasurer

Time: 11 a.m. EST&nbsp;

Company: <a href="https://ir.volition.com/">VolitionRx Limited</a>

Ticker: (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#NYSE">VNRX</a>)&nbsp;

Industry: Epigenetics &mdash; cancer screening and veterinary&nbsp;

Speaker information: Scott Powell, head of investor relations and U.S. chief financial officer

Time: 11:30 a.m. EST&nbsp;

Company: <a href="https://www.otcmarkets.com/stock/MCURF/overview">Mind Cure Health Inc.</a>

Ticker: (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/MCURF#OTCQX">MCURF</a>)&nbsp;

Industry: Pharmaceuticals &mdash;&nbsp; psychedelics and mental health

Speaker Information: Kelsey Ramsden, president and CEO

Time: 12 p.m. EST&nbsp;

Company: <a href="https://www.otcmarkets.com/stock/ACOGF/overview">Alpha Cognition</a>, Inc.

Tickers: (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/ACOGF#OTCQB">ACOGF</a>), (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#TSXV">ACOG</a>)&nbsp;

Industry: Biopharmaceuticals &mdash; Alzheimer&rsquo;s disease and amyotrophic lateral sclerosis (ALS)

Speaker information: Michael McFadden, CEO

Time: 12:30 p.m. EST&nbsp;

Company: <a href="https://www.otcmarkets.com/stock/EMMA/overview">Emmaus Life Sciences Inc.</a>

Ticker: (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/EMMA#OTCQX">EMMA</a>)&nbsp;

Industry: Biopharmaceuticals &mdash; rare and orphan diseases&nbsp;

Speaker information: Yutaka Niihara, CEO and chairman

Time: 1 p.m. EST&nbsp;

Company: <a href="https://www.otcmarkets.com/stock/HMTXF/overview">Hemostemix Inc.</a>&nbsp;

Tickers: (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/HMTXF#OTCQB">HMTXF</a>), (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/HEM#TSXV">HEM</a>)&nbsp;

Industry: Biotechnology &mdash; stem cell therapies

Speaker information: Thomas Smeenk, co-founder, president and CEO

Time: 1:30 p.m. EST&nbsp;

Company: <a href="https://www.otcmarkets.com/stock/JNHMF/overview">Jack Nathan Medical Corp</a>.

Tickers: (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/JNHMF#OTCQB">JNHMF</a>), (TSX:-V JNH)&nbsp;

Industry: Primary-care medical clinics

Speaker information: Glenn Copeland, CEO and chief medical officer,&nbsp; David Berman, chief financial officer

Time: 2 p.m. EST&nbsp;

Company: <a href="https://ir.reshapelifesciences.com/">ReShape Lifesciences Inc.</a>

Ticker: (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>)&nbsp;

Industry: Weight loss and metabolic health

Speaker information: Bart Bandy, CEO and president, Tom Stankovich, CFO

Time: 2:30&nbsp; p.m. EST&nbsp;

Company: <a href="https://www.otcmarkets.com/stock/BABYF/profile">Else Nutrition Holdings Inc.</a>

Ticker: (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/BABYF#OTCQX">BABYF</a>), (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/BABY#TSXV">BABY</a>)&nbsp;

Industry: Plant-based nutrition

Speaker information: Hamutal Yitzhak, founder and CEO

Time: 3 p.m. EST&nbsp;

Company: <a href="http://investors.salariuspharma.com/">Salarius Pharmaceuticals, Inc.</a>

Ticker: (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>)&nbsp;

Industry: Biotechnology - Cancer

Speaker information: David Arthur, CEO

A complete list of the agenda is available on the <a href="https://www.virtualinvestorconferences.com/events/event-details/life-sciences-investor-forum-3?utm_source=121621LSIF&amp;utm_medium=article+&amp;utm_campaign=121621LSIF&amp;utm_id=120221SmallCapVIC">Life Science Investor Forum</a>&rsquo;s main page.&nbsp;

The preceding post was written and/or published as a collaboration between Benzinga&rsquo;s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.

Comments

Hemostemix

News

Latest news for Hemostemix (OTC:HMTXF) Stock

Tuesday, December 14, 2021

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga